Your search
Results 8 resources
-
COVID-19 is a pandemic with a rapidly increasing incidence of infections and deaths. Many pharmacologic therapies are being used or considered for treatment. Given the rapidity of emerging literature, IDSA felt the need to develop living, frequently updated evidence-based guidelines to support patients, clinicians and other health-care professionals in their decisions about treatment and management of patients with COVID-19 infection. Summarized here are the recommendations with comments...
-
The Infectious Diseases Society of America and the American Association for the Study of Liver Diseases have collaboratively developed evidence-based guidance regarding the diagnosis, management, and treatment of hepatitis C virus (HCV) infection since 2013. A panel of clinicians and investigators with extensive infectious diseases or hepatology expertise specific to HCV infection periodically review evidence from the field and update existing recommendations or introduce new recommendations...
-
Abstract. These clinical practice guidelines are an update of the guidelines published by the Infectious Diseases Society of America (IDSA) in 2009, prior to t
-
PurposeTo provide an updated joint ASCO/Infectious Diseases Society of America (IDSA) guideline on antimicrobial prophylaxis for adult patients with immunosuppression associated with cancer and its treatment.MethodsASCO and IDSA convened an update Expert Panel and conducted a systematic review of relevant studies from May 2011 to November 2016. The guideline recommendations were based on the review of evidence by the Expert Panel.ResultsSix new or updated meta-analyses and six new primary...
-
IDSA Guidelines on Antigen Testing for the Diagnosis of COVID-19 now available. These evidence-based rapid guidelines will address pressing clinical questions related to optimal use of SARS-CoV-2 Antigen tests in both medical and non-medical settings.
-
SARS-CoV-2 is a highly transmissible virus that can infect health care personnel and patients in health care settings. Specific care activities, in particular aerosol-generating procedures, may have a higher risk of transmission. The rapid emergence and global spread of SARS-CoV-2 has created significant challenges in health care facilities, particularly with severe shortages of personal protective equipment (PPE) used to protect health care personnel (HCP). Summarized here are the...
-
Serologic tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are now widely available. IDSA has developed recommendations related to the use of SARS-CoV-2 serologic testing in clinical practice and public health.
-
Direct detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acids in respiratory tract specimens informs patient, healthcare institution, and public health level decision-making. IDSA has developed an evidence-based diagnostic guideline to assists clinicians, clinical laboratorians, patients and policymakers in decisions related to the optimal use of SARS-CoV-2 nucleic acid amplification tests.
Filter by our tag
GUIDELINES
ORGANISMS
-
VIRUSES
- CMV (1)
-
COVID-19
(5)
- Diagnosis (3)
- GUIDELINES (5)
- Infection Prevention (1)
- Treatments (1)
- Hepatitis B (1)
- Hepatitis C (1)
- Influenza (1)
- Respiratory Viruses (1)
DRUGS AND THERAPIES
- Antifungals (1)
SOLID ORGANS AND MCSS
- Liver (1)
HEME-ONC AND CELLULAR THERAPIES
- BMT Basics (1)
- Heme-onc prophylaxis (1)
- Neutropenia (1)